Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q4 FY23 results · Jan–Mar 2023
Solara Active Pharma Sciences reported revenue from operations of ₹380.62 crore (up 5.5% from Q4 FY22) and net profit of ₹3.76 crore (up 107.7% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 380.62 | 360.82 | +5.5% | 394.75 | −3.6% |
| Other income | 4.68 | 6.07 | −22.9% | 7.17 | −34.7% |
| Total income | 385.30 | 366.89 | +5.0% | 401.92 | −4.1% |
| Profit before tax | 5.04 | (31.00) | Turned profit | 0.55 | +816.4% |
| Net profit for the period | 3.76 | 1.81 | +107.7% | 0.43 | +774.4% |
| Attributable to shareholders of the company | 3.77 | 1.88 | +100.5% | 0.45 | +737.8% |
| EPS, basic (₹) | 1.05 | 0.53 | +98.1% | 0.12 | +775.0% |
| Net margin (%) | 1.0 | 0.5 | 0.1 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 380.62 | 360.82 | +5.5% | 394.75 | −3.6% |
| Other income | 5.12 | 4.69 | +9.2% | 6.77 | −24.4% |
| Total income | 385.74 | 365.51 | +5.5% | 401.52 | −3.9% |
| Profit before tax | 8.31 | (32.88) | Turned profit | 0.53 | 16x |
| Net profit for the period | 6.46 | 0.22 | 29x | 0.42 | 15x |
| EPS, basic (₹) | 1.79 | 0.06 | 30x | 0.12 | 15x |
| Net margin (%) | 1.7 | 0.1 | 0.1 |
Consolidated
- Filed with BSE
- 13 May 2023, 12:30 IST
- Board meeting
- 12 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 May 2023, 12:30 IST
- Board meeting
- 12 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE